Marksans Pharma Share Price
Small Cap | Pharmaceuticals and health care | NSE: MARKSANS | BSE: 524404
₹225.00 
-7.40 (-3.18 %)
Last Updated: 21 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 236.20
High (₹) 236.40
Low (₹) 224.50
Prev. Close (₹) 232.40
Volume 35,954
VWAP (₹) 230.02
ROCE (%) 18.97
Industry P/E 43.99
TTM P/E 27.68
P/B Ratio 4.91
Market Cap (₹) Cr.10,243.77
Dividend Yield (%)0.27
EPS (₹) 6.92
ROE15.03%
Sales Growth (%) 17.56
Profit Growth (%)18.68
Day Range
236.40236.40
52 Week Range
126.05358.50
Historical Returns
Returns (6M)
-4.11 %
Returns (1Y)
42.18 %
Returns (3Y)
364.4 %
Returns (5Y)
1062.79 %
Returns (6M)
-4.11 %
Returns (1Y)
42.18 %
Returns (3Y)
364.4 %
Returns (5Y)
1062.79 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with (7.96%) TTM EPS Growth
- Company with Low Debt
- Book value per share improving over the last 2 years
- Company with 7.96% positive TTM EPS growth
- Increasing Annual Revenue for Past 2 Years
- Increasing Revenue every Quarter for the past 4 Quarters
- Bullish MACD crossover (12,6,9) indicates potential upward price movement.
Technicals
Technical Rating
BEARISHRSI 44.40
MFI 36.52
ATR 15.82
Commodity Channel Index -97.49
ROC125 -0.37
ROC21 -10.58
Williams %R -96.07
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 233.50 | 240.90 | 245.40 | 229.00 | 221.60 | 217.10 | 209.70 |
| Week Ago | 247.15 | 263.70 | 273.15 | 237.70 | 221.15 | 211.70 | 195.15 |
| Month Ago | 269.74 | 280.27 | 286.14 | 263.87 | 253.34 | 247.47 | 236.94 |
EMA & SMA
225.00
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 234.94
9 Day 241.51
10 Day 246.50
12 Day 251.60
14 Day 247.81
20 Day 243.70
26 Day 248.37
50 Day 270.31
100 Day 285.69
200 Day 242.66
Deals & Announcements
Bulk and Block Deals
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 06 Jun, 2024 | Sandra Saldanha | Acquisition | ₹141.4820943169606169795815159 | 63,276 | BSE |
| 04 Jun, 2024 | Sandra Saldanha | Acquisition | ₹146.0071702127659574468085106 | 47,000 | BSE |
| 22 Aug, 2023 | Arvind Singh | Acquisition | ₹115.75 | 3,000 | BSE |
| 22 Aug, 2023 | Arvind Singh | Disposal | ₹163.9215 | 2,000 | BSE |
| 22 Aug, 2023 | Arvind Singh | Disposal | ₹114.9016666666666666666666667 | 3,000 | BSE |
| 22 Aug, 2023 | Arvind Singh | Disposal | ₹117.0553846153846153846153846 | 6,500 | BSE |
| 16 Mar, 2023 | Sandra Saldanha | Acquisition | ₹66.69 | 1,45,000 | BSE |
| 02 Mar, 2023 | Mark Saldanha | Acquisition | ₹74.00 | 10,00,000 | BSE |
| 01 Mar, 2023 | Sandra Saldanha | Acquisition | ₹67.46033333333333333333333333 | 75,000 | BSE |
| 02 Mar, 2020 | Mr. Sebastian Pereira | Disposal | ₹108.5950980392156862745098039 | 5,100 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 30 May, 2024 | Rs.0.6000 per share(60%)Final Dividend | 17 Sept, 2024 | 17 Sept, 2024 |
| 25 May, 2023 | Rs.0.5000 per share(50%)Final Dividend | 07 Jun, 2023 | 07 Jun, 2023 |
| 30 May, 2022 | Rs.0.2500 per share(25%)Final Dividend | 19 Aug, 2022 | 01 Jan, 1970 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 12 Feb, 2025 | BSE India | Kindly find enclosed intimation for uploading of audio recording of Investor(s) / analyst(s) meet - Q3FY2024-25 Financial Results Conference Call |
| 12 Feb, 2025 | NSE India | Marksans Pharma Limited has informed the Exchange about Link of Recording |
| 11 Feb, 2025 | NSE India | Marksans Pharma Limited has informed the Exchange regarding a revised press release dated February 11, 2025, titled ""Revised press release"". |
| 11 Feb, 2025 | BSE India | Kindly find enclosed revised press release of financial results for quarter ended December 31, 2024 |
| 11 Feb, 2025 | BSE India | Kindly find enclosed |
| 11 Feb, 2025 | NSE India | Integrated filing - Financial |
| 11 Feb, 2025 | BSE India | Kindly find enclosed |
| 11 Feb, 2025 | NSE India | Marksans Pharma Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 |
| 11 Feb, 2025 | BSE India | Kindly find enclosed |
| 11 Feb, 2025 | BSE India | Kindly find enclosed |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 23 Jan, 2025 | 11 Feb, 2025 |
| Quarterly Results | -- | 24 Oct, 2024 | 12 Nov, 2024 |
| Quarterly Results | -- | 01 Aug, 2024 | 13 Aug, 2024 |
| Audited Results & Final Dividend | -- | 14 May, 2024 | 30 May, 2024 |
| Quarterly Results | -- | 18 Jan, 2024 | 13 Feb, 2024 |
| Quarterly Results | -- | 30 Oct, 2023 | 09 Nov, 2023 |
| Quarterly Results | -- | 03 Aug, 2023 | 11 Aug, 2023 |
| Audited Results & Final Dividend | -- | 18 May, 2023 | 30 May, 2023 |
| Quarterly Results | -- | 06 Feb, 2023 | 13 Feb, 2023 |
| Others | Inter alia, to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis. | 12 Jan, 2023 | 20 Jan, 2023 |
Share Holding Pattern
| Owner Name | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sept, 2023 |
|---|
About Marksans Pharma
Marksans Pharma is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 853.27 Cr. and Equity Capital is Rs. 45.32 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1992
Managing Director
Mr. Mark Saldanha
NSE Symbol
MARKSANS
Marksans Pharma Management
| Name | Designation |
|---|---|
| Mr. Mark Saldanha | Chairman & Managing Director |
| Mrs. Sandra Saldanha | Whole Time Director |
| Mr. Varddhman V Jain | Whole Time Director |
| Dr. Sunny Sharma | Non Executive Director |
| Mr. Seetharama R Buddharaju | Independent Director |
| Mr. Digant Mahesh Parikh | Independent Director |
| Mr. Abhinna Sundar Mohanty | Independent Director |
| Mrs. Shailaja Vardhan | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,643.75  ₹1,669.30(-1.53%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,757.05 ₹5,978.30(-3.70%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,475.75 ₹1,479.70(-0.27%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,327.75 ₹2,348.45(-0.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,151.80 ₹1,170.95(-1.64%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Marksans Pharma
What is the share price of Marksans Pharma?
The share price of Marksans Pharma on 21 Feb, 2025 is ₹ 225.00.
What is 52W high and 52W low share price of Marksans Pharma?
The highest and lowest 52W share prices of Marksans Pharma are ₹ 358.500 and ₹ 126.050
What is the market cap of Marksans Pharma?
The market capitalization of Marksans Pharma as of 21 Feb, 2025 is ₹ 10,243.77 Crores
What is the P/E ratio of Marksans Pharma?
The current P/E ratio of Marksans Pharma as of 21 Feb, 2025 is 43.99
What is the PB ratio of Marksans Pharma?
The PB ratio of Marksans Pharma as of 21 Feb, 2025 is 4.91
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)